The market for stem cells is constantly evolving, with researches going on to exploit the true potential of the market worldwide. Stem cell has emerged as an important market in the US which continues to witness massive investments in this research arena. US has seen some major achievements in the treatment of diseases using stem cell technologies. The market has shown remarkable growth since 2005, when the first stem cell product entered into the market. The stem cell market is expected to register a CAGR growth of around 69% in a short period spanning from 2010 to 2012, says our new research report, “US Stem Cell Market Analysis”.
The prevalence of major chronic diseases like cancer, Parkinson’s diseases and spinal cord injury among people and the dependency on medicines for sustainability and well-being provides the ready market for the stem cell companies to tap. Moreover, the high cost of treatments for these diseases has boosted the demand for these products in the market.
Our team of industry experts has found that the restrictions imposed by the Bush Administration eight years back on the federal funding of embryonic stem cells research had had negative impact on the US embryonic stem cell product market. But the Obama Administration has lifted up the restrictions and opened up new growth avenues. The report gives comprehensive information in this regard. On technological front, this report studies the stem cells market as therapeutic banking and cellular therapeutics. Besides, other emerging trends, like cord blood banking market, have also been analyzed extensively in the report.
“US Stem Cell Market Analysis” provides extensive research and thorough analysis of the current industry trends and factors which are driving the growth of stem cell market in the US. This report highlights the emerging segments in the market along with their potential to serve the country’s population. The report will help clients to understand the market dynamics and get an insight of the current and the future outlook of stem cells market in the US.
